IRIS
CARACCIOLO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.558
AS - Asia 1.025
EU - Europa 754
SA - Sud America 223
AF - Africa 23
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 3.593
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.504
SG - Singapore 479
IT - Italia 443
CN - Cina 231
BR - Brasile 169
DE - Germania 101
IN - India 97
VN - Vietnam 88
GB - Regno Unito 72
HK - Hong Kong 40
SE - Svezia 35
CA - Canada 34
FI - Finlandia 34
BD - Bangladesh 18
NL - Olanda 16
ID - Indonesia 13
MX - Messico 13
AR - Argentina 12
FR - Francia 11
ZA - Sudafrica 11
EC - Ecuador 10
JP - Giappone 9
RU - Federazione Russa 9
VE - Venezuela 8
EU - Europa 7
AT - Austria 6
CO - Colombia 6
ES - Italia 6
IQ - Iraq 6
PY - Paraguay 6
UZ - Uzbekistan 6
CL - Cile 5
KE - Kenya 5
PK - Pakistan 5
UA - Ucraina 5
CZ - Repubblica Ceca 4
JO - Giordania 4
TR - Turchia 4
AU - Australia 3
CH - Svizzera 3
EG - Egitto 3
LB - Libano 3
NP - Nepal 3
PE - Perù 3
AZ - Azerbaigian 2
ET - Etiopia 2
IR - Iran 2
LT - Lituania 2
MA - Marocco 2
OM - Oman 2
PL - Polonia 2
SA - Arabia Saudita 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LV - Lettonia 1
MM - Myanmar 1
MY - Malesia 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 3.593
Salva come PNG Salva come JPEG
Città #
San Jose 278
Singapore 210
Ashburn 163
Chandler 152
Dallas 79
Santa Clara 78
Munich 71
Bengaluru 66
Hefei 66
Beijing 52
Chicago 50
London 49
Catanzaro 46
Lawrence 44
Milan 44
Princeton 44
Hong Kong 37
Ho Chi Minh City 31
Naples 26
Hanoi 23
Turku 22
Los Angeles 18
Wilmington 18
Rome 16
São Paulo 16
New York 15
Des Moines 13
Ottawa 13
Carbonia 12
Helsinki 12
Parma 12
Brooklyn 11
Montreal 10
Boardman 9
Cosenza 8
Ercolano 8
Redwood City 8
San Nicola Manfredi 8
Santo Stefano di Rogliano 8
Afragola 7
Boston 6
Catania 6
Dhaka 6
Manchester 6
Melito di Porto Salvo 6
Reggio Calabria 6
Stockholm 6
Tashkent 6
Charlotte 5
Chennai 5
Columbus 5
Guangzhou 5
Nairobi 5
Orem 5
Seattle 5
Settingiano 5
Shanghai 5
The Dalles 5
Amman 4
Aversa 4
Bologna 4
Brescia 4
Buffalo 4
Can Tho 4
Da Nang 4
Decollatura 4
Frankfurt am Main 4
Haiphong 4
Hanover 4
Jakarta 4
Jiaxing 4
Johannesburg 4
Mexico City 4
Mountain View 4
New Delhi 4
Pune 4
Redmond 4
Rio de Janeiro 4
Thái Bình 4
Tokyo 4
Acquaviva delle Fonti 3
Ahmedabad 3
Atlanta 3
Belo Horizonte 3
Berlin 3
Biên Hòa 3
Cape Town 3
Castrovillari 3
Denver 3
Guayaquil 3
Madrid 3
Manaus 3
Mileto 3
Nova Iguaçu 3
Nuremberg 3
Olomouc 3
Palermo 3
Paola 3
Phoenix 3
Porto Alegre 3
Totale 2.099
Salva come PNG Salva come JPEG
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 138
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 110
miR-22 suppresses DNA ligase III addiction in multiple myeloma 102
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 98
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 93
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 87
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 85
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 82
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 75
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 74
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 72
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 72
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 71
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 70
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 69
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 68
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 66
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 65
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 64
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 60
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 59
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 59
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 57
Mir-221/222 are promising targets for innovative anticancer therapy 56
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 56
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 55
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 55
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 54
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 54
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 54
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 54
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 52
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 51
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 51
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 51
Integration of DNA Microarray with Clinical and Genomic Data 51
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 51
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 50
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 50
Mmrf-commpass data integration and analysis for identifying prognostic markers 50
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 49
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 46
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 44
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 44
Alternative non-homologous end-joining: Error-prone dna repair as cancer’s achilles’ heel 44
null 43
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 41
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 40
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 40
The potential role of miRNAs in multiple myeloma therapy 39
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 37
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 36
The potential role of miRNAs in multiple myeloma therapy 34
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. 34
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 34
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches 32
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma 31
null 31
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 30
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. 26
Synthetic miR-22 impairs NHEJ repair sensistizing multiple myeloma cells to bortezomib-induced BRCAness 26
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 25
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 24
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 22
Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase 16
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 13
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 9
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 7
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 2
Totale 3.730
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.834
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.834
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202140 0 0 0 0 0 0 0 0 0 20 15 5
2021/2022179 4 0 0 27 7 5 11 30 37 31 24 3
2022/2023541 95 29 32 21 64 38 6 39 76 54 68 19
2023/2024320 86 32 36 22 16 83 7 6 1 5 10 16
2024/2025886 88 26 29 37 59 132 39 45 70 10 130 221
2025/20261.623 111 184 168 227 196 84 244 83 211 115 0 0
Totale 3.730